Note from the editor: Small but important changes ahead

By Jenni Spinner contact

- Last updated on GMT

(We Are/iStock via Getty Images Plus)
(We Are/iStock via Getty Images Plus)

Related tags: Decentralized trials, Clinical trials, Clinical trial, Patient centricity, Contract research organization, Clinical research, Drug development, Pharmaceutical industry

The past two years have been full of shifts and shakes in the drug development field, but the change at Outsourcing-Pharma is easy and one for the better.

Flexibility is a necessary survival skill in this day and age. If someone can’t adapt to keep up with the times, they will let their customers down and risk falling behind.

Sometimes, the changes required to keep pace are difficult—a good example appropriate to Outsourcing-Pharma might be changing course from on-site studies to decentralized trials. In other instances, adaptation is less of a struggle yet still worth making (switching your daily cola at lunch to a diet to save on calories).

The change we’re making at Outsourcing-Pharma definitely falls into the latter camp. True, it’s an adjustment for both us and our readers; however, it’s a fairly easy transition that will lead to a range of worthwhile benefits across the board.

Readers like you are more engaged with our publication than ever before. In 2019, our content had about 767,000 views in a year; just two years later, in 2021, that same number was about 1.2m. That shows us we’re headed in the right direction, in terms of delivering the industry coverage you and your colleagues are interested in.

The next step in ensuring we deliver the best drug-development content possible is deepening the connection with readers like you. We will be asking our audience to register and provide a few professional details. It’s a minor inconvenience but one that will empower our team to:

  • Craft the content of most use and interest to you and your colleagues
  • Put together email newsletters that contain on-point industry news
  • Provide information about online events and resources of top value to you
  • Keep you up to date on developments in the segments you are most interested in.

Without registration, visitors will still be able to read up to two articles in a 30-day period. However, to read more OSP content than that, we ask you to take a moment to register.

If you are a current newsletter subscriber (thank you for your patronage), you will still need to register to read more than two articles every 30 days. Don’t worry; you will keep receiving the email updates that you already opted-in for (visit our email preference hub to manage them).

What’s more, Outsourcing-Pharma only requires registration for unlimited access to our news content. Readers like you can visit our other pages (resources, promotional features listing pages, and the homepage) without registration.

Thank you for continuing to be a loyal Outsourcing-Pharma reader. It’s true that change can be difficult, but this one is easy and will enable us to serve readers like you even better in the future.

Related news

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...



Indena | 25-Oct-2022 | Technical / White Paper

Indena is well known in the space of naturally derived molecules, with a know-how developed over its one hundred year history. At the same time, the company...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

Related suppliers

Follow us


View more